Shilpa Medicare Ltd
SHILPAMEDShilpa Medicare Ltd
SHILPAMED


Price Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
75.32 | 3.69 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
48.59 | 6.21 | 0.55% |
Forecast & Ratings
Detailed Forecast from 2 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Shilpa Medicare Limited is engaged in the business of manufacturing of bulk drugs or active pharmaceutical ingredient (API) and intermediates, and wind power generation.
Investor Presentation
View olderÂPeers
Compare with peersÂGet more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 724.00 | 798.83 | 810.50 | 786.96 | 924.85 | 992.11 | 1,168.76 | 1,067.51 | 1,165.90 | 1,271.85 | ||||||||||
Raw Materials | 374.23 | 418.27 | 313.83 | 256.81 | 293.78 | 329.56 | 390.24 | 401.45 | 442.33 | 941.00 | ||||||||||
Power & Fuel Cost | 24.44 | 26.30 | 28.86 | 33.57 | 38.76 | 40.25 | 52.43 | 56.79 | 52.41 | |||||||||||
Employee Cost | 91.45 | 127.87 | 149.35 | 176.40 | 196.59 | 235.31 | 264.49 | 286.39 | 281.49 | |||||||||||
Selling & Administrative Expenses | 49.33 | 48.39 | 59.02 | 54.50 | 115.69 | 104.32 | 158.09 | 116.55 | 97.93 | |||||||||||
Operating & Other expenses | 26.96 | -2.26 | 82.79 | 84.26 | 43.65 | 11.77 | 80.28 | 90.46 | 37.72 | |||||||||||
EBITDA | 157.59 | 180.26 | 176.65 | 181.42 | 236.38 | 270.90 | 223.23 | 115.87 | 254.02 | 330.85 | ||||||||||
Depreciation/Amortization | 28.63 | 30.64 | 37.22 | 42.06 | 43.78 | 53.98 | 79.80 | 95.50 | 107.87 | 110.83 | ||||||||||
PBIT | 128.96 | 149.62 | 139.43 | 139.36 | 192.60 | 216.92 | 143.43 | 20.37 | 146.15 | 220.02 | ||||||||||
Interest & Other Items | 6.86 | 3.13 | 2.66 | 3.68 | 4.56 | 21.87 | 41.17 | 58.65 | 91.81 | 85.24 | ||||||||||
PBT | 122.10 | 146.49 | 136.77 | 135.68 | 188.04 | 195.05 | 102.26 | -38.28 | 54.34 | 134.78 | ||||||||||
Taxes & Other Items | 18.32 | 38.92 | 31.52 | 23.42 | 31.91 | 47.27 | 41.60 | -5.75 | 22.47 | 46.49 | ||||||||||
Net Income | 103.78 | 107.57 | 105.25 | 112.26 | 156.13 | 147.78 | 60.66 | -32.53 | 31.87 | 88.29 | ||||||||||
EPS | 13.46 | 13.68 | 13.02 | 13.77 | 19.15 | 18.13 | 7.21 | -3.75 | 3.67 | 10.17 | ||||||||||
DPS | 0.60 | 0.60 | 0.70 | 1.00 | 1.10 | 1.10 | 1.10 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.04 | 0.04 | 0.05 | 0.07 | 0.06 | 0.06 | 0.15 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Shilpa Medicare Ltd | 208.65 | 3.69 | — |
Sun Pharmaceutical Industries Ltd | 43.75 | 6.24 | 0.77% |
Cipla Ltd | 28.85 | 4.44 | 0.88% |
Torrent Pharmaceuticals Ltd | 62.82 | 15.18 | 0.91% |
Price Comparison
Compare SHILPAMED with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Apr 2024
Jun 2024
Sep 2024
Dec 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Shilpa Medicare Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2429% | Percentage of the fund’s portfolio invested in the stock 0.89% | Change in the portfolio weight of the stock over the last 3 months -0.18% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 110/203 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.1267% | Percentage of the fund’s portfolio invested in the stock 0.54% | Change in the portfolio weight of the stock over the last 3 months -0.11% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 57/88 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0279% | Percentage of the fund’s portfolio invested in the stock 1.39% | Change in the portfolio weight of the stock over the last 3 months -0.41% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 22/55 (-7) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2022
Dividend/Share
₹1.10
Ex DateEx Date
Sep 19, 2022
Cash Dividend
Ex DateEx DateSep 20, 2021
Dividend/Share
₹1.10
Ex DateEx Date
Sep 20, 2021
Cash Dividend
Ex DateEx DateMar 16, 2020
Dividend/Share
₹1.10
Ex DateEx Date
Mar 16, 2020
Cash Dividend
Ex DateEx DateSep 12, 2019
Dividend/Share
₹1.00
Ex DateEx Date
Sep 12, 2019
Cash Dividend
Ex DateEx DateMar 1, 2018
Dividend/Share
₹0.70
Ex DateEx Date
Mar 1, 2018
Shilpa Medicare announces the approval of its IND - Nor Ursodeoxycholic Acid Tablets 500 mg, by the Subject Expert Committee of CDSCO. The Committee has further recommended grant of marketing authorization for this IND for the treatment of non-alcoholic fatty liver disease (NAFLD). Shilpa Medicare Ltd. had earlier completed phase-3 clinical studies of this novel product SMLNUD07 - Nor Ursodeoxycholic Acid (Nor UDCA) tablets - and presented the results of the trial titled 'A phase - III, Randomized, Double- Blind, placebo controlled, multicenter, Parallel group study' to evaluate the safety and efficacy of Nor-Ursodeoxycholic Acid 500 mg in patients suffering from Non-alcoholic Fatty Liver Disease to the SEC. This trial was a multicentric, placebo controlled double blinded study conducted on total 165 Non-alcoholic fatty liver disease (NAFLD) patients across India - a significant statistically powered number of patients leading to better reliability of data and results. No serious adverse events were reported in this phase 3 study and the treatment was well tolerated at the dose of 1500 mg per day for the duration of 24 weeks. The Phase 3 trial has met all the primary efficacy endpoints set in the clinical trial protocol, demonstrating a significant improvement in fatty liver stage. In this study 165 participants were randomised to assess and compare the efficacy and safety of nor UDCA 1500 mg against placebo. The data analysis has confirmed that liver fibrosis stage was reversed in significant majority of participants (83.3%) and stabilised in rest, within 24 weeks of nor UDCA treatment. (Primary endpoint) The elevated alanine transaminase (ALT) levels of NAFLD were normalized in significant proportion of participants (~90%) within 12 weeks of study (Primary endpoint). These results indicate that Nor UDCA could become a new standard of care with significant improvements in restoring liver function in NAFLD patients. This IND is expected to revolutionise the treatment of patients suffering from Nonalcoholic Fatty Liver Disease (NAFLD). Â Â Â Powered by Capital Market - Live
Net profit of Shilpa Medicare rose 593.89% to Rs 31.78 crore in the quarter ended December 2024 as against Rs 4.58 crore during the previous quarter ended December 2023. Sales rose 11.35% to Rs 319.32 crore in the quarter ended December 2024 as against Rs 286.76 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales319.32286.76 11 OPM %25.2722.72 - PBDT70.4240.87 72 PBT41.6114.17 194 NP31.784.58 594 Powered by Capital Market - Live
Revenue from operations was at Rs 319.32 crore, up 11.35% year on year, driven by healthy performance in fast-growing verticals, viz. (finished dosage forms) FDF and biologics. EBITDA jumped 20% to Rs 82 crore in Q3 FY25 from Rs 68 crore registered in Q3 FY24. EBITDA margin improved to 26% in Q3 FY25 from 24% in Q3 FY24. Total expenses were up by 2.09% year on year to Rs 279.18 crore in the quarter ended 31 December 2024. The cost of materials consumed stood at Rs 89.98 crore (down 14.95% YoY), while employee benefits expense was at Rs 73.49 crore (up 6.44% YoY). On a nine-month basis, the company's consolidated net profit zoomed 765.40% to Rs 63.78 crore in 9M FY25 as compared to Rs 7.37 crore recorded in 9M FY24. Revenue from operations jumped 11.13% YoY to Rs 955.62 crore in 9M FY25. Vishnukant Bhutada, managing director of Shilpa Medicare, said, 'Our 3QFY25 performance reflects robust growth in profitability driven by an improved business mix. The quarter witnessed healthy YoY growth in our key verticals of FDF on the biologics front, we have initiated Ph3 trials for Aflibercept; and we have initiated commercial launch quantities for OLC, a US CDMO opportunity. I am also highly optimistic on receiving approval for our NCE'NorUDCA'in this financial year. With positive traction on our new product launches in the coming quarters, I am confident of delivering strong revenue growth in each business vertical. Going forward, our focus remains on scaling up API business, launching approved NDAs in regulated markets, and getting timely approvals on filed products. We continue to invest in future pipelines as well as focus on resolutions on the regulatory front. Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India. Shares of Shilpa Medicare tanked 5.96% to currently trade at Rs 686.95 on the BSE.Powered by Capital Market - Live
Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 10 February 2025.Powered by Capital Market - Live
The approved drug is indicated for the treatment of erectile dysfunction (sometimes called impotence) in adult males. The total Europe market for oral Tadalafil formulations is estimated at about $400 million. The drug maker stated that it becomes the first company in the world to receive approval for this product as a convenient, patient friendly oral mouth dissolving/dispersing film formulation. This approval is a hybrid application and Shilpa's product is bioequivalent to the reference product. The approval has been granted for the company's finished dosage form manufacturing facility, Unit VI, located in Dabaspet, Bengaluru, Karnataka. Currently approved by the MHRA UK, this marks the second approval for a prescription oral mouth-dissolving film product in the European/UK regulated markets from this facility. It is involved in the manufacturing, packaging, labeling, and testing of finished dosage forms, including oral dispersible/dissolving films and transdermal patches. Raichur-based Shilpa Medicare is a vertically integrated manufacturer and distributor of quality drugs to global markets, specializing in the oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance. The company's consolidated net profit soared to Rs 17.94 crore in Q2 FY25 as against Rs 1.61 crore posted in Q2 FY24. Revenue from operations rose 9.8% to Rs 343.80 crore in the quarter ended 30 September 2024. The scrip tumbled 3.85% to currently trade at Rs 778.35 on the BSE. Powered by Capital Market - Live
Both units of Shilpa Medicare's (Unit IV and Unit VII) have now received GMP approval of Eurasia, the member countries for which are Belarus, Russia, Kazakhstan, Kyrgyzstan, and Armenia. This approval will open up significant business opportunities in these countries. Unit IV of Shilpa Medicare is engaged in the manufacture, testing, release and distribution of sterile Injectable and non-sterile Oral finished dosage forms in the US, Europe and rest of the world markets. Unit VII of Shilpa Medicare is engaged in testing raw materials, packing materials, finished dosage forms, and other testing activities. Raichur-based Shilpa Medicare is a vertically integrated manufacturer and distributor of quality drugs to global markets, specializing in the oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance. The company's consolidated net profit soared to Rs 17.94 crore in Q2 FY25 as against Rs 1.61 crore posted in Q2 FY24. Revenue from operations rose 9.8% to Rs 343.80 crore in the quarter ended 30 September 2024. The scrip shed 0.33% to currently trade at Rs 767.30 on the BSE. Powered by Capital Market - Live
Shilpa Medicare, Unit IV, Jadcherla, Telangana, India and Shilpa Medicare, Unit VII, Nacharam, Hyderabad, Telangana, India had undergone a GMP inspection by Ministry of Health, Belarus for GMP certification from the Eurasian Economic Union in October 2024. Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval of Eurasia, the member countries for which are Belarus, Russia, Kazakhstan, Kyrgyzstan and Armenia. This approval will open up significant business opportunities in these countries. Unit IV of Shilpa Medicare is engaged in the manufacture, testing, release and distribution of sterile Injectable and non-sterile Oral finished dosage forms in the US, Europe and rest of the world markets. Unit VII of Shilpa Medicare is engaged in testing raw materials, packing materials, finished dosage forms and other testing activities.Powered by Capital Market - Live
The inspection was conducted from 24 September 2024 to 26 September 2024. On conclusion of the inspection the company has received the Good Manufacturing Practice (GMP) Certification. Unit VII of Shilpa Medicare houses an Analytical Services Division (QC) and a Bio-Analytical Department, both of which are approved by the USFDA. Notably, the Bio-Analytical Laboratory is already approved by EMA, Europe. This inspection was the first Europe inspection for the QC laboratory of Unit VII. This Laboratory is involved in testing drug substances, raw materials, packing materials and finished products. It is also engaged in other analytical activities like analytical method validations, method transfers and other miscellaneous analytical studies. The laboratory has been testing samples for final release into US, EU and other markets. Raichur-based Shilpa Medicare is a vertically integrated manufacturer and distributor of quality drugs to global markets, specializing in the oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance. The company's consolidated net profit soared to Rs 17.94 crore in Q2 FY25 as against Rs 1.61 crore posted in Q2 FY24. Revenue from operations rose 9.8% to Rs 343.80 crore in the quarter ended 30 September 2024. The scrip shed 0.03% to Rs 828.75 on the BSE. Powered by Capital Market - Live
Oncosol is 50:50 joint venture between Liqmeds Lifecare, a Zydus Group company, and Koana Healthcare, a Shilpa Medicare Group company. IMKELDI is an advanced liquid formulation of imatinib designed for dosing accuracy. It helps slow or prevent the growth of specific cancers, including chronic myeloid leukemia (CML), acute lymphoblastic leukemia, myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), and gastrointestinal tumors (GIST). 'In 2024, an estimated 9,280 people will be diagnosed with CML, over 10,000 with MDS/MPD, and up to 6,000 with GIST in the U.S. Despite the proven clinical benefits of imatinib, patient adherence can be an issue, underscoring a critical unmet need for a more accessible, patient-friendly oral solution delivery system,' the company stated in exchange filing. Raichur-based Shilpa Medicare is a vertically integrated manufacturer and distributor of quality drugs to global markets, specializing in the oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance. The company's consolidated net profit soared to Rs 17.94 crore in Q2 FY25 as against Rs 1.61 crore posted in Q2 FY24. Revenue from operations rose 9.8% to Rs 343.80 crore in the quarter ended 30 September 2024. The scrip rose 0.42% to Rs 892.50 on the BSE.Powered by Capital Market - Live
Albumin is in high demand for various medical treatments, including restoring blood volume and replacing lost fluids during accidents, serious burn injuries, fatal erythroblastosis, hypoproteinemia, and surgeries. However, the supply of human serum albumin is limited due to the reliance on whole blood or donated human plasma. Shilpa's Recombinant Human Albumin 20% (rHA), derived from yeast, offers a highly purified, structurally and functionally equivalent alternative to human serum albumin. The company has successfully completed its Phase I clinical trials on 7 August 2024. With today's announcement, the company confirms that the SEC has accepted the trial results and approved the progression to Phase III trials for rHA 20%. The Phase III trials will be conducted according to the protocol approved by the SEC. Shilpa is the first company in India to receive the approval for conducting Phase III clinical trials. This approval clears regulatory strategy for India and various emerging markets that accept Indian studies and is an important step towards providing a reliable and safe alternative to human serum albumin, addressing the global demand and supply challenges. Raichur-based Shilpa Medicare is a vertically integrated, manufacturer and distributor of quality drugs to global markets; specializing in the oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance. The company's consolidated net profit soared to Rs 17.94 crore in Q2 FY25 as against Rs 1.61 crore posted in Q2 FY24. Revenue from operations rose 9.8% to Rs 343.80 crore in the quarter ended 30 September 2024. The scrip shed 0.66% to Rs 889.25 on the BSE. Powered by Capital Market - Live
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 8.18%, vs industry avg of 9.04%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.36% to 0.31%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -22.26%, vs industry avg of 15.28%